Figure 6.
Co-delivery of docetaxel–siRNA in treatment of cancer. Suppression of the proliferation and metastasis of cancer cells is provided using siRNA-ATG7, p65, MMP-9, and MAPK. This results in increase in cytotoxicity of DTX docetaxel against cancer cells. Nanoparticles provide a platform for co-delivery of docetaxel and siRNA in triggering chemosensitivity.